gouda aged 3 year
Selected indexed studies
- Effects of intensive blood-pressure control in type 2 diabetes mellitus. (N Engl J Med, 2010) [PMID:20228401]
- Effects of intensive glucose lowering in type 2 diabetes. (N Engl J Med, 2008) [PMID:18539917]
- Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. (Lancet, 2015) [PMID:25530442]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Effects of intensive glucose lowering in type 2 diabetes. (2008) pubmed
- Effects of intensive blood-pressure control in type 2 diabetes mellitus. (2010) pubmed
- Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. (2019) pubmed
- Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. (2017) pubmed
- Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT. (2024) pubmed
- Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly. (2025) pubmed
- Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. (2022) pubmed
- Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. (2015) pubmed
- Disease-modifying antirheumatic drug-free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study. (2025) pubmed
- First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. (2025) pubmed